After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac Surgery
Abstract Vasoplegic syndrome (VS) comprises a constellation of concurrent signs and symptoms: hypotension, high cardiac index, low systemic vascular resistance, low filling pressures, the tendency to occur diffuse bleeding, and sustained hypotension. All of these parameters may persist even despite...
Main Authors: | Paulo Roberto B. Evora, Ricardo O. S. Soares, Solange Bassetto, Maria Auxiliadora Martins, Fábio Luis da Silva Silva, Anibal Basile Filho |
---|---|
Format: | Article |
Language: | English |
Published: |
Sociedade Brasileira de Cirurgia Cardiovascular
2021-08-01
|
Series: | Brazilian Journal of Cardiovascular Surgery |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382021000300406&tlng=en |
Similar Items
-
Early Use of Methylene Blue in Vasoplegic Syndrome: A 10-Year Propensity Score-Matched Cohort Study
by: Othmar Kofler, et al.
Published: (2022-02-01) -
Methylene blue for vasodilatory shock in the intensive care unit: a retrospective, observational study
by: Emily E. Naoum, et al.
Published: (2022-06-01) -
Definitions and pathophysiology of vasoplegic shock
by: Simon Lambden, et al.
Published: (2018-07-01) -
Efficacy of methylene blue for on vasoplegic syndrome
by: Mohsen akhondi, et al.
Published: (2016-04-01) -
Use of methylene blue to treat vasoplegia syndrome in cystic fibrosis patients undergoing lung transplantation: A case series
by: Gabriel C Washington, et al.
Published: (2023-01-01)